SCHEDULE: Innovative Cellular Therapeutics Discloses 9.8% Stake in Lyell Immunopharma

Innovative Cellular Therapeutics Holdings Ltd has reported a 9.8% beneficial ownership stake in Lyell Immunopharma, Inc., totaling 1.9 million shares.

Summary

• Innovative Cellular Therapeutics Holdings Ltd (Reporting Person), a Cayman Island exempted company, has acquired beneficial ownership of 1,900,000 shares of Common Stock in Lyell Immunopharma, Inc. (Issuer).
• This ownership represents 9.8% of Lyell Immunopharma, Inc.'s outstanding Common Stock, calculated based on 19,296,408 shares outstanding as of October 21, 2025.
• The Reporting Person holds sole voting power and sole dispositive power over all 1,900,000 shares.
• The acquisition was not made for the purpose of changing or influencing control of the issuer, nor in connection with any transaction having that purpose or effect, other than activities solely related to a nomination under Rule 240.14a-11.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The filing is a mandatory disclosure of a significant ownership stake, which is generally a neutral event. However, a substantial investment by another entity can be seen as a vote of confidence in the issuer, hence a slight positive lean.

Positives

• Innovative Cellular Therapeutics Holdings Ltd has established a significant beneficial ownership position in Lyell Immunopharma, Inc., indicating potential strategic interest or investment confidence in the issuer.

Future Outlook

NA

Management Comments

• I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

This filing indicates a significant investment by a Cayman Islands-based entity, Innovative Cellular Therapeutics Holdings Ltd, into a U.S. biotechnology company, Lyell Immunopharma, Inc. Such an investment could signal confidence in Lyell's pipeline or a broader strategic interest in the cellular therapeutics space, which is a rapidly evolving sector within the biotechnology industry.

Stakeholder Impact

• Shareholders of Lyell Immunopharma, Inc. may view this as a positive signal, indicating external investor confidence and potentially increased liquidity or strategic interest in the company.

Key Dates

Keywords

Lyell Immunopharma, Innovative Cellular Therapeutics, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Biotechnology, Investment, Equity Stake